PT  - JOURNAL ARTICLE
AU  - Koole, Michel
AU  - Lewis, Dewi M.
AU  - Buckley, Christopher
AU  - Nelissen, Natalie
AU  - Vandenbulcke, Mathieu
AU  - Brooks, David J.
AU  - Vandenberghe, Rik
AU  - Van Laere, Koen
TI  - Whole-Body Biodistribution and Radiation Dosimetry of <sup>18</sup>F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging
AID  - 10.2967/jnumed.108.060756
DP  - 2009 May 01
TA  - Journal of Nuclear Medicine
PG  - 818--822
VI  - 50
IP  - 5
4099  - http://jnm.snmjournals.org/content/50/5/818.short
4100  - http://jnm.snmjournals.org/content/50/5/818.full
SO  - J Nucl Med2009 May 01; 50
AB  - We have characterized the biodistribution and dosimetry of 18F-3′-F-6-OH-BTA1 (18F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects. Methods: Six subjects (5 men and 1 woman; age range, 51–74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of 18F-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined. Results: No adverse events or clinically significant changes were observed. 18F-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 μGy/MBq, respectively). The mean effective dose was 33.8 ± 3.4 μSv/MBq, a dose comparable to that of many other 18F-labeled radiopharmaceuticals. Conclusion: The estimated effective dose of 18F-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.